Our first test for uveal melanoma, a rare and deadly eye cancer, is used to identify those at high risk for metastasis. With demonstrated improved accuracy over existing staging and prognostic tools, the test has become the standard of care for uveal melanoma and has successfully secured reimbursement. We are using its innovation as a model for our growing lineup of practice-changing tests, including our newer cutaneous (skin) melanoma prognostic assay. We have active development programs for assays in several other underserved cancers.
Castle Biosciences’ tests are performed in a CLIA-certified, CAP-accredited clinical laboratory.